PepGen Inc. PEPG

Company Overview

PepGen Inc. is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics intended to improve delivery and uptake into target tissues, particularly skeletal muscle and the central nervous system. The company operates within the biotechnology and rare disease sectors, with a primary emphasis on neuromuscular and neurological disorders. PepGen’s core technology platform combines engineered cell-penetrating peptides with oligonucleotides to enhance intracellular delivery, an area that has historically limited the effectiveness of many RNA-based therapies.

The company’s principal revenue and value drivers are its therapeutic development programs, including candidates targeting Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). PepGen’s strategic positioning is centered on its proprietary enhanced delivery peptide (EDP) platform, which the company states is designed to improve tissue penetration and therapeutic potency relative to conventional oligonucleotide approaches. PepGen was founded in 2018 by researchers associated with the University of Oxford ecosystem and subsequently expanded operations into the United States. The company became publicly traded on Nasdaq under the ticker PEPG in 2022.